These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32345264)

  • 41. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.
    Zhang S; Lai X; Li W; Xiong Z; Xu A; Xu A; Huang L
    Thromb Res; 2014 Dec; 134(6):1272-7. PubMed ID: 25457586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of
    Pilling LC; Türkmen D; Fullalove H; Atkins JL; Delgado J; Kuo CL; Kuchel GA; Ferrucci L; Bowden J; Masoli JAH; Melzer D
    BMJ Open; 2021 Dec; 11(12):e053905. PubMed ID: 34903548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.
    Joo HJ; Ahn SG; Park JH; Park JY; Hong SJ; Kim SY; Choi W; Gwon H; Lim YH; Kim W; Kang WC; Cho YH; Kim YH; Yoon J; Shin W; Hong MK; Garg S; Jang Y; Lim DS
    Sci Rep; 2018 Jan; 8(1):1229. PubMed ID: 29352151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
    Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
    Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
    Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Pan Y; Wangqin R; Li H; Wang Y; Meng X; Johnston SC; Simon T; Lin J; Zhao X; Liu L; Wang D; Wang Y
    Neurology; 2021 Jan; 96(1):e1-e9. PubMed ID: 33093222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
    Song TJ; Kim J; Han SW; Kim YD; Lee JY; Ahn SH; Lee HS; Jung YH; Lee KY
    BMJ Open; 2020 Aug; 10(8):e038031. PubMed ID: 32759249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy.
    Zhang S; Zhu J; Li H; Li F; Zhu B; Li T; Fang S; Qin S
    Pharmacogenet Genomics; 2022 Jun; 32(4):138-143. PubMed ID: 34954768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction among
    Yi X; Lin J; Wang Y; Zhou J; Zhou Q
    Oncotarget; 2017 Sep; 8(41):70811-70820. PubMed ID: 29050321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
    Rosafio F; Lelli N; Mimmi S; Vandelli L; Bigliardi G; Dell'Acqua ML; Picchetto L; Pentore R; Ferraro D; Trenti T; Nichelli P; Zini A
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1864-1873. PubMed ID: 28576652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interactions among variants in
    Yi X; Lin J; Luo H; Zhou J; Zhou Q; Wang Y; Wang C
    Oncotarget; 2018 Apr; 9(25):17597-17607. PubMed ID: 29707133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
    McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
    J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
    Pan Y; Chen W; Xu Y; Yi X; Han Y; Yang Q; Li X; Huang L; Johnston SC; Zhao X; Liu L; Zhang Q; Wang G; Wang Y; Wang Y
    Circulation; 2017 Jan; 135(1):21-33. PubMed ID: 27806998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or transient ischaemic attack.
    Wang T; Pan Y; Lin J; Anand R; Wang D; Johnston SC; Meng X; Li H; Zhao X; Liu L; Wang Y; Wang Y;
    Eur J Neurol; 2019 Sep; 26(9):1175-1182. PubMed ID: 30974489
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.